Madrigal Pharmaceuticals, Inc. (MDGL)
511.84
-4.90
(-0.95%)
USD |
NASDAQ |
Aug 24, 16:00
511.84
0.00 (0.00%)
After-Hours: 20:00
Madrigal Pharmaceuticals Profit Margin (Quarterly) : -15.91% for June 30, 2026
Profit Margin (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -15.91% |
| March 31, 2026 | -30.32% |
| December 31, 2025 | -18.24% |
| September 30, 2025 | -39.75% |
| June 30, 2025 | -19.87% |
| March 31, 2025 | -53.36% |
| December 31, 2024 | -57.51% |
| September 30, 2024 | -172.0% |
| June 30, 2024 | -1.04K% |
| March 31, 2024 | |
| December 31, 2023 | |
| September 30, 2023 | |
| June 30, 2023 | |
| March 31, 2023 | |
| December 31, 2022 | |
| September 30, 2022 | |
| June 30, 2022 | |
| March 31, 2022 | |
| December 31, 2021 | |
| September 30, 2021 | |
| June 30, 2021 | |
| March 31, 2021 | |
| December 31, 2020 | |
| September 30, 2020 | |
| June 30, 2020 |
| Date | Value |
|---|---|
| March 31, 2020 | |
| December 31, 2019 | |
| September 30, 2019 | |
| June 30, 2019 | |
| March 31, 2019 | |
| December 31, 2018 | |
| September 30, 2018 | |
| June 30, 2018 | |
| March 31, 2018 | |
| December 31, 2017 | |
| September 30, 2017 | |
| June 30, 2017 | |
| March 31, 2017 | |
| December 31, 2016 | |
| September 30, 2016 | |
| June 30, 2016 | |
| March 31, 2016 | |
| December 31, 2015 | |
| September 30, 2015 | |
| June 30, 2015 | |
| March 31, 2015 | |
| December 31, 2014 | |
| September 30, 2014 | |
| June 30, 2014 | |
| March 31, 2014 |
Profit Margin Definition
Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.
Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Profit Margin (Quarterly) Benchmarks
| Insmed, Inc. | -3.11% |
| PTC Therapeutics, Inc. | 23.16% |
| Protagonist Therapeutics, Inc. | 76.28% |
| Exelixis, Inc. | 33.73% |
| Karyopharm Therapeutics, Inc. | -200.5% |
Profit Margin (Quarterly) Related Metrics
| Return on Equity | -54.34% |
| Return on Assets | -26.61% |
| Return on Invested Capital | -36.08% |
| Gross Profit Margin (Quarterly) | 88.91% |
| Operating Margin (Quarterly) | -15.46% |
| Return on Net Operating Assets | -134.0% |